公开(公告)号：WO2010132953A1

公开(公告)日：2010-11-25

申请号：PCT/AU2010/000614

申请日：2010-05-21

Applicant: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION ,  MACDONALD, James, Matthew ,  ADHIKARI, Raju ,  POSTMA, Almar ,  HIRAI, Tadahiko ,  UENO, Kazunori

Inventor： MACDONALD, James, Matthew ,  ADHIKARI, Raju ,  POSTMA, Almar ,  HIRAI, Tadahiko ,  UENO, Kazunori

IPC: C07D487/16 ,  C09K11/06 ,  H01L51/54

CPC classification number: C07D487/16 ,  C09K11/06 ,  C09K2211/1007 ,  C09K2211/1011 ,  C09K2211/1014 ,  C09K2211/1029 ,  C09K2211/1059 ,  C09K2211/1088 ,  C09K2211/1092 ,  C09K2211/1425 ,  H01L51/0072 ,  H05B33/10

Abstract: The present invention relates to an organic electroluminescent device comprising a pair of electrodes forming an anode and cathode, and one or more layers of organic compound arranged between the pair of electrodes, wherein the organic compound layer comprises heptaazaphenalene derivatives of formula (1). The present invention also relates to the said compounds.

Abstract translation: 本发明涉及一种包含形成阳极和阴极的一对电极和布置在该对电极之间的一层或多层有机化合物的有机电致发光器件，其中有机化合物层包含式（1）的七氮杂萘衍生物。 本发明还涉及所述化合物。

公开(公告)号：WO2009000237A1

公开(公告)日：2008-12-31

申请号：PCT/DE2008/000995

申请日：2008-06-20

Applicant: NOVALED AG ,  LIMMERT, Michael ,  LUX, Andrea ,  HARTMANN, Horst

Inventor： LIMMERT, Michael ,  LUX, Andrea ,  HARTMANN, Horst

IPC: C07D487/16 ,  C09K11/06 ,  H01L51/50 ,  H01L51/00 ,  H05B33/14

CPC classification number: C07D487/16 ,  H01L51/002 ,  H01L51/0052 ,  H01L51/0059 ,  H01L51/0072 ,  H01L51/0094 ,  H01L51/5012 ,  H01L51/5052 ,  H01L51/5088 ,  H01L51/5096 ,  Y02E10/549 ,  Y10S428/917 ,  Y10T428/265 ,  Y10T428/31504

Abstract: Verwendung eines Precursors eines n-Dotanden zur Dotierung eines organischen halbleitenden Materials, als Blockerschicht, als Ladungsinjektionsschicht, als Elektrodenmaterial, als Speichermaterial oder als Halbleitermaterial selbst in elektronischen oder optoelektronischen Bauelementen, wobei der Precursor ausgewählt wird aus den folgenden Formeln (1-3c).

Abstract translation: 使用n型掺杂剂用于掺杂有机半导体材料，作为阻挡层，作为电荷注入层，作为电极材料，作为记忆材料或作为半导体材料本身在电子或光电元件，其中，所述前体选自下式（1-3C）选择的前体。

公开(公告)号：WO2008083975A1

公开(公告)日：2008-07-17

申请号：PCT/EP2008/000173

申请日：2008-01-11

Applicant: ISDIN S.A. ,  ANTONIO PUIG, S.A. ,  GORCHS CAPA, Olga ,  JIMENEZ ALONSO, Oscar ,  TRULLAS CABANAS, Carlos Ramon ,  CORBERA ARJONA, Jordi ,  PANYELLA COSTA, David

Inventor： GORCHS CAPA, Olga ,  JIMENEZ ALONSO, Oscar ,  TRULLAS CABANAS, Carlos Ramon ,  CORBERA ARJONA, Jordi ,  PANYELLA COSTA, David

IPC: C07D487/16 ,  C08K5/3492

CPC classification number: C07D487/16 ,  C08K5/3492

Abstract: The present invention relates to a light-stabilized composition comprising at least one polymer and 0.01 to 25 % by weight, based on the total weight of the composition, of a light-stabilizing component comprising at least one heptaazaphenalene compound of general formula (I), wherein the radicals R 1 , R 2 and R 3 are defined in the description, optionally in combination with at least one further light stabilizer (Z), articles, moulds, sheets, foils or films produced of such light-stabilized composition, the use of at least one heptaazaphenalene compound of general formula (I) as a light stabilizer for polymers as well as to a light stabilizer combination comprising at least one of said heptaazaphenalene and at least one further light-stabilizer (Z).

Abstract translation: 本发明涉及包含至少一种聚合物和基于组合物总重量的0.01至25重量％的光稳定组合物，其包含至少一种通式（I）的七氮杂萘化合物， ，其中基团R 1，R 2和R 3 3在说明书中定义，任选地与至少一种其它光稳定剂（ Z），由这种光稳定组合物制成的制品，模具，片材，箔片或薄膜，使用至少一种通式（I）的七氮杂萘化合物作为聚合物的光稳定剂以及光稳定剂组合， 所述七氮杂萘和至少一种其它光稳定剂（Z）中的至少一种。

公开(公告)号：WO2007013964A1

公开(公告)日：2007-02-01

申请号：PCT/US2006/028154

申请日：2006-07-21

Applicant: SUNESIS PHARMACEUTICALS, INC. ,  OSLOB, Johan, D. ,  YU, Chul, Hyun

Inventor： OSLOB, Johan, D. ,  YU, Chul, Hyun

IPC: C07D487/04 ,  C07D487/16 ,  A61K31/519 ,  A61P9/00 ,  A61P19/00 ,  A61P25/00 ,  A61P29/00 ,  A61P35/00

CPC classification number: C07D487/04

Abstract: The present invention provides compounds having the formula: (I) wherein A-B together represent one of the following structures: (II) or (III) wherein one of ---- is a double bond, as valency permits; and R 2 , R 4 , X 1A , X 2A , X 1B , X 2B , L 1 , L 2 , Y an Z are as defined in classes and subclasess herein, and pharmaceutical compositions thereof, as described generally and in subclasses herein, which compounds are useful as inhibitors of protein kinase (e.g., Aurora), and thus are useful, for example, for the treatment of Aurora mediated diseases.

Abstract translation: 本发明提供具有下式的化合物：其中A-B一起代表以下结构之一：（II）或（III）其中一个是双键，化合价允许; 和R 2，R 4，X 1A，X 2A，X 1B， ，X 2B，L 1，L 2，Y和Z如本文中的类别和亚临界所定义，及其药物组合物，如所述 通常和在本文中的亚类中，哪些化合物可用作蛋白激酶（例如，Aurora）的抑制剂，因此可用于例如治疗Aurora介导的疾病。

公开(公告)号：WO2005030144A3

公开(公告)日：2005-10-27

申请号：PCT/US2004031571

申请日：2004-09-23

Applicant: SQUIBB BRISTOL MYERS CO ,  SALVATI MARK E ,  ILLIG CARL R ,  WILSON KENNETH JEROME ,  CHEN JINSHENG ,  MEEGALLA SANATH K ,  WALL MARK JAMES

Inventor： SALVATI MARK E ,  ILLIG CARL R ,  WILSON KENNETH JEROME ,  CHEN JINSHENG ,  MEEGALLA SANATH K ,  WALL MARK JAMES

IPC: A61K31/5025 ,  A61K45/06 ,  C07D487/04 ,  C07D487/16 ,  A61P5/28 ,  A61P35/00 ,  C07D487/14

CPC classification number: C07D487/04 ,  A61K31/5025 ,  A61K45/06 ,  C07D519/00 ,  A61K2300/00

Abstract: Disclosed are pyrrolopyridazine compounds, methods of preparing such compounds, and their use for the treatment of proliferative, inflammatory, and other disorders.

Abstract translation: 公开了吡咯并哒嗪化合物，制备这些化合物的方法，以及它们用于治疗增殖性，炎性和其他疾病的用途。

公开(公告)号：WO2005066178A1

公开(公告)日：2005-07-21

申请号：PCT/JP2005/000323

申请日：2005-01-06

Applicant: TAISHO PHARMACEUTICAL CO., LTD. ,  NAKAZATO, Atsuro ,  OKUBO, Taketoshi ,  NOZAWA, Dai ,  TAMITA, Tomoko ,  KENNIS, Ludo, E.J.

Inventor： NAKAZATO, Atsuro ,  OKUBO, Taketoshi ,  NOZAWA, Dai ,  TAMITA, Tomoko ,  KENNIS, Ludo, E.J.

IPC: C07D487/16

CPC classification number: C07D487/16

Abstract: An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc. A triaza-cyclopenta[cd]indene derivative represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.

Abstract translation: 本发明的目的是提供一种抗CRF受体的拮抗剂，其作为治疗或预防药物是有效的，其涉及CRF被认为涉及的疾病，例如抑郁症，焦虑症，阿尔茨海默病，帕金森病，亨廷顿舞蹈病，饮食 疾病，高血压，胃疾病，药物依赖，癫痫，脑梗塞，脑缺血，脑水肿，头部外伤，炎症，免疫相关疾病，特异性，肠易激综合征，睡眠障碍，皮肤病，精神分裂症，疼痛等。 由下式[I]表示的三氮杂 - 环戊二烯并[cd]茚衍生物：对CRF受体具有高亲和力，并且对于CRF被认为涉及的疾病有效。

公开(公告)号：WO2005065150A2

公开(公告)日：2005-07-21

申请号：PCT/US2004/041555

申请日：2004-12-10

Applicant: KORONIS PHARMACEUTICALS, INC. ,  DAIFUKU, Richard ,  GALL, Alexander ,  SERGUEEV, Dmitri

Inventor： DAIFUKU, Richard ,  GALL, Alexander ,  SERGUEEV, Dmitri

IPC: C07D405/12 ,  C07D487/04 ,  C07D487/16

CPC classification number: C07D405/12 ,  C07D487/04 ,  C07D487/16 ,  C07H13/12 ,  C07H17/02 ,  C07H19/12 ,  C07H19/23

Abstract: The present invention provides compounds as well as methods of using the compounds as antiviral and anti-cancer chemotherapeutic agents.

Abstract translation: 本发明提供化合物以及使用该化合物作为抗病毒和抗癌化学治疗剂的方法。

公开(公告)号：WO2004048384A1

公开(公告)日：2004-06-10

申请号：PCT/EP2003/013322

申请日：2003-11-26

Applicant: NAD AG ,  MONSE, Barbara ,  BRAXMEIER, Tobias ,  FERRAND, Sandrine ,  GORDON, Sandra ,  KLAFKI, Hans ,  LAHU, Gezim ,  RODER, Hanno ,  SAHAGUN-KRAUSE, Heidi ,  SENECI, Pierfausto ,  THILLAYE DU BOULLAY, Olivier

Inventor： MONSE, Barbara ,  BRAXMEIER, Tobias ,  FERRAND, Sandrine ,  GORDON, Sandra ,  KLAFKI, Hans ,  LAHU, Gezim ,  RODER, Hanno ,  SAHAGUN-KRAUSE, Heidi ,  SENECI, Pierfausto ,  THILLAYE DU BOULLAY, Olivier

IPC: C07D487/16

CPC classification number: C07D487/22

Abstract: The present invention relates to novel protein kinase inhibitors with advantageous pharmaceutical properties, methods for their preparation, intermediates thereof and pharmaceutical compositions comprising the same, reagents containing the same, and methods of using the same as therapeutics, particularly in CNS diseases.

Abstract translation: 本发明涉及具有有利药学性质的新型蛋白激酶抑制剂，其制备方法，其中间体和包含其的药物组合物，含有其的试剂以及使用其作为治疗剂，特别是CNS疾病的方法。

公开(公告)号：WO02098855A3

公开(公告)日：2003-03-13

申请号：PCT/US0217564

申请日：2002-05-31

Applicant: MCDONNELL THOMAS E ,  KOPPES WILLIAM M ,  SITZMANN MICHAEL E

Inventor： MCDONNELL THOMAS E ,  KOPPES WILLIAM M ,  SITZMANN MICHAEL E

IPC: C06C15/00 ,  C07D487/04 ,  C07D487/16 ,  C06B45/20

CPC classification number: C07D487/04 ,  C06C15/00 ,  Y10S149/119

Abstract: The present invention includes a precursor compound pertaining to a 1,2,4-Triazolo[4,3-a][1,3,5] Triazine compound, particularly a 1,2,4-Triazolo[4,3-a][1,3,5]Triazine-3,5,7-Triamine, and novel fused ring structures such as triazolyl-tetrazinyl-aminotriazine compounds, and complexes and salts thereof, and other such chemical structures.

Abstract translation: 本发明包括涉及1,2,4-三唑并[4,3-a] [1,3,5]三嗪化合物，特别是1,2,4-三唑并[4,3-a] [1,3,5]三嗪-3,5,7-三胺，以及新型稠环结构如三唑基 - 四嗪基 - 氨基三嗪化合物及其络合物和盐以及其它这些化学结构。

公开(公告)号：WO00077010A2

公开(公告)日：2000-12-21

申请号：PCT/US2000/016373

申请日：2000-06-15

IPC: C07D487/04 ,  A61K31/435 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/4985 ,  A61K31/5383 ,  A61K31/542 ,  A61K31/55 ,  A61K31/553 ,  A61K31/554 ,  A61P1/00 ,  A61P3/04 ,  A61P15/00 ,  A61P25/00 ,  A61P25/06 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P43/00 ,  C07D221/18 ,  C07D223/32 ,  C07D407/08 ,  C07D409/08 ,  C07D471/04 ,  C07D471/06 ,  C07D471/14 ,  C07D471/16 ,  C07D487/16 ,  C07D491/06 ,  C07D495/06 ,  C07D498/16 ,  C07D513/04 ,  C07D513/16 ,  C07D519/00 ,  A61K31/4353

CPC classification number: C07D471/06 ,  C07D221/18 ,  C07D223/32 ,  C07D491/06 ,  C07D495/06

Abstract: The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R , R , R , R , R , R , R , X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

Abstract translation: 本发明涉及由结构式（I）表示的某些新化合物或这些化合物的药学上可接受的盐。 在该式中，R 1，R 5，R 6a，R 6b，R 7，R 8，R 9，X，b，k，m和n和 虚线在应用程序中描述。 本发明还涉及包含这些新化合物作为活性成分的药物制剂以及这些新化合物及其制剂在治疗某些病症中的用途。 这些化合物是激动剂和血清素拮抗剂，并用于阻止或防止中枢神经系统的紊乱如肥胖症，焦虑症，抑郁症，精神病，精神分裂症，睡眠障碍，性功能障碍，偏头痛，疼痛相关的病症 头部，社交恐怖症和胃肠道疾病，例如消化道运动障碍。